Advertisement

La radiologia medica

, Volume 124, Issue 2, pp 136–144 | Cite as

Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian Association of Radiation Oncology (AIRO)—Lung Working Group

  • Giuseppe ParisiEmail author
  • Rosario Mazzola
  • Patrizia Ciammella
  • Giorgia Timon
  • Alessandra Fozza
  • Davide Franceschini
  • Federico Navarria
  • Alessio Bruni
  • Marco Perna
  • Niccolò Giaj-Levra
  • Filippo Alongi
  • Vieri Scotti
  • Marco Trovo
RADIOTHERAPY
  • 73 Downloads

Abstract

A systematic literature was performed to assess the benefit in terms of effectiveness and feasibility of hypofractionated radiotherapy (HypoRT), with or without chemotherapy (CT), in the treatment of locally advanced non-small cell lung cancer (NSCLC). We have identified all studies, published from 2007 onwards, on patients with locally advanced NSCLC treated with HypoRT with radical intent, with a minimal dose per fraction of 2.4 Gy, with or without concurrent chemotherapy. Twenty-nine studies were identified, for a total of 2614 patients. Patients were divided in the concurrent chemo-radiation therapy group (CT-RT) and radiotherapy alone (RT). In RT group, the delivered dose ranged from 45 to 85.5 Gy, with a dose/fraction from 2.4 to 4 Gy. Actuarial 2-year PFS ranged from 13 to 57.8%, and 1, 2- and 3-year overall survival (OS) ranged from 51.3 to 95%, from 22 to 68.7%, and from 7 to 32%, respectively. Acute Grade ≥ 3 esophagitis occurred in 0–15%, while late esophageal toxicity was 0–16%. Acute pneumonitis occured in 0–44%, whereas late pneumonitis occured in 0–47%, most commonly grade ≤ G3. In CT-RT group, the delivered dose ranged from 52.5 to 75 Gy, with a dose/fraction ranging from 2.4 to 3.5 Gy. Actuarial 2-year PFS ranged from 19 to 57.8%, and OS at 1, 2 and 3 years ranged from 28 to 95%, 38.6 to 68.7%, and 31 to 44%, respectively. Acute Grade 2 and 3 esophagitis occurred in 3–41.7%, while late esophageal toxicity occurred in 0–8.3%. Acute pneumonitis ranged from 0 to 23%, whereas late pneumonitis occured 0–47%. HypoRT seems to be safe in patients with locally advanced NSCLC. The encouraging survival results of several studies analyzed suggest that hypofractionated radiation schemes should be further investigated in the future.

Keywords

Hypofractionated radiotherapy Chemotherapy NSCLC Treatment Toxicity 

Notes

Author contribution statements

In our review are listed 13 authors. The authors’ contribution is listed: GP and MT wrote the article independently reviewed the citations and were responsible for analyzing and interpreting the data. RM wrote the manuscript in consultation with GP and MT. PC, GT, AF, DF, FN, AB, MP NJL, FA, VS contributed to design, bibliographic search and implementation of the review. FN drafted the article. All authors contributed to the analysis of the results, discussed the results and commented the manuscript. GP and MT revised its content to its final version. All authors approved the final manuscript.

Compliance with ethical Standards

Conflict of interest

All authors declare no conflict of interest.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    National Cancer Institute (2018) SEER cancer statistics factsheets: lung and bronchus cancer. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/statisfacts/html/lungb.html. Accessed 12 Jan 2018
  2. 2.
    Siegel R, De Santis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E (2012) Cancer treatment and survivorship statistics. CA Cancer J Clin 62(4):220–241.  https://doi.org/10.3322/caac.21149 CrossRefGoogle Scholar
  3. 3.
    Mauguen A, Le Pechoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, Sause WT, Ball D, Belani CP, Bonner JA, Zajusz A, Dahlberg SE, Nankivell M, Mandrekar SJ, Paulus R, Behrendt K, Koch R, Bishop JF, Dische S, Arriagada R, De Ruysscher D, Pignon JP (2012) Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 30:2788–2797.  https://doi.org/10.1200/JCO.2012.41.6677 CrossRefGoogle Scholar
  4. 4.
    Network NCC (2018) NCCN clinical practice guidelines in oncology non-small cell lung cancer version 2.2018—December 19, 2017. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 12 Jan 2018
  5. 5.
    Aupèrin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28(13):2181–2190.  https://doi.org/10.1200/JCO.2009.26.2543 CrossRefGoogle Scholar
  6. 6.
    Perez CA, Stanley K, Rubin P, Kramer S, Brady L, Perez-Tamayo R, Brown GS, Concannon J, Rotman M, Seydel HG (1980) A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by Radiation Therapy Oncology Group. Cancer 45:2744–2753CrossRefGoogle Scholar
  7. 7.
    Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in non resectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83(6):417–423CrossRefGoogle Scholar
  8. 8.
    Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W, Emami B (2005) Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61(2):318–328.  https://doi.org/10.1016/j.ijrobp.2004.06.260 CrossRefGoogle Scholar
  9. 9.
    Fowler JF, Chappell R (2000) Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys 46(2):516–517.  https://doi.org/10.1016/s0360-3016(99)00364-8 CrossRefGoogle Scholar
  10. 10.
    Machtay M, Hsu C, Komaki R, Sause WT, Swann RS, Langer CJ, Byhardt RW, Curran WJ (2005) Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys 63(3):667–671.  https://doi.org/10.1016/j.ijrobp.2005.03.037 CrossRefGoogle Scholar
  11. 11.
    Machtay M, Bae K, Movsas B, Paulus R, Gore EM, Komaki R, Albain K, Sause WT, Curran WJ (2012) Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 82:425–434.  https://doi.org/10.1016/j.ijrobp.2010.09.004 CrossRefGoogle Scholar
  12. 12.
    Oh D, Ahn YC, Kim B, Pyo H (2013) Hypofractionated three-dimensional conformal radiation therapy alone for centrally located cT1-3 N0 non-small-cell lung cancer. J Thorac Oncol 8:624–629.  https://doi.org/10.1097/JTO.0b013e31828cb6db CrossRefGoogle Scholar
  13. 13.
    Beli I, Koukourakis G, Platoni K, Tolia M, Kelekis N, Kouvaris J, Syrigos C, Mystakidou K, Varveris C, Kouloulias V (2010) Hypofractionated radiotherapy in non small cell lung cancer: a review of the current literature. Rev Recent Clin Trials 5:103–111.  https://doi.org/10.2174/157488710791233608 CrossRefGoogle Scholar
  14. 14.
    Prewett SL, Aslam S, William MV, Gillingan D (2012) The management of lung cancer: a UK survey of oncologists. Clin Oncol (R Coll Radiol) 24:402–409.  https://doi.org/10.1016/j.clon.2012.03.005 CrossRefGoogle Scholar
  15. 15.
    Uitterhoeve ALJ, Koolen MJK, van Os RM, Koedooder K, van de Kar M, Pieters BR, Koning CCE (2007) Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with non-small cell lung cancer. Radiat Oncol 2:27.  https://doi.org/10.1186/1748-717X-2-27 CrossRefGoogle Scholar
  16. 16.
    Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, Van de Vaart P, Price A, van Walree N, Legrand C, Dussenne S, Bartelink H, Giaccone G, Koning C (2007) EORTC LCG and RT Group, Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 43(1):114–121.  https://doi.org/10.1016/j.ejca.2006.09.005 CrossRefGoogle Scholar
  17. 17.
    Adkison JB, Khuntia D, Bentzen SM, Cannon GM, Tome WA, Jaradat H, Walker W, Traynor AM, Weigel T, Mehta MP (2008) Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I dose escalation study. Technol Cancer Res Treat 7:441–447.  https://doi.org/10.1177/153303460800700605 CrossRefGoogle Scholar
  18. 18.
    Kepka L, Tyc-Szczepaniak D, Bujko K (2009) Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer. J Thorac Oncol 4(7):853–861.  https://doi.org/10.1097/JTO.0b013e3181a97dda CrossRefGoogle Scholar
  19. 19.
    Pemberton LS, Din OS, Fisher PM, Hatton MQ (2009) Accelerated radical radiotherapy for non small cell lung cancer using two common regimens: a single-centre retrospective study of outcome. Clin Oncol 21:161–167.  https://doi.org/10.1016/j.clon.2008.11.016 CrossRefGoogle Scholar
  20. 20.
    Amini A, Lin SH, Wei C, Allen P, Cox JD, Komaki R (2012) Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non small cell lung cancer. Radiat Oncol 7:33.  https://doi.org/10.1186/1748-717X-7-33 CrossRefGoogle Scholar
  21. 21.
    Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tomé WA, Chappell RJ, Tolakanahalli R, Mohindra P, Bentzen SM, Cannon GM (2013) Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol 31:4343–4348.  https://doi.org/10.1200/jco.2013.51.5353 CrossRefGoogle Scholar
  22. 22.
    Gomez DR, Gillin M, Liao Z, Wei C, Lin SH, Swanick C, Alvarado T, Komaki R, Cox JD, Chang JY (2013) Phase 1 study of dose escalation in hypofractionated proton beam therapy non-small cell lung cancer. Int J Radiat Oncol Biol Phys 86(4):665–670.  https://doi.org/10.1016/j.ijrobp.2013.03.035 CrossRefGoogle Scholar
  23. 23.
    Osti MF, Agolli L, Valeriani M, Falco T, Bracci S, De Sanctis V, Enrici RM (2013) Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 85(3):157–163.  https://doi.org/10.1016/j.ijrobp.2012.10.012 CrossRefGoogle Scholar
  24. 24.
    Din OS, Harden SV, Hudson E, Mohammed N, Pemberton LS, Lester JF, Biswas D, Magee L, Tufail A, Carruthers R, Sheikh G, Gilligan D, Hatton MQ (2013) Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centers. Radiother Oncol 109:8–12.  https://doi.org/10.1016/j.radonc.2013.07.014 CrossRefGoogle Scholar
  25. 25.
    Zhu ZF, Fan M, Wu KL, Zhao KL, Yang HJ, Chen GY, Jiang GL, Wang LJ, Zhao S, Fu XL (2011) A Phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer. Radiother Oncol 98:304–308.  https://doi.org/10.1016/j.radonc.2011.01.022 CrossRefGoogle Scholar
  26. 26.
    Maguire J, Khan I, McMenemin R, O’Rourke N, McNee S, Kelly V, Peedell C, Snee M (2014) SOCCAR: a randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III non-small cell lung cancer and good performance status. Eur J Cancer 50(17):2939–2949.  https://doi.org/10.1016/j.ejca.2014.07.009 CrossRefGoogle Scholar
  27. 27.
    Westhover KD, Loo BW Jr, Gerber DE, Iyengar P, Choy H, Diehn M, Hughes R, Schiller J, Dowell J, Wardak Z, Sher D, Christie A, Xie XJ, Corona I, Sharma A, Wadsworth ME, Timmerman R (2015) Precision hypofractionated radiation therapy in poor performing patients with non-small cell lung cancer: phase 1 dose escalation trial. Int J Rad Oncol Biol Phys 93(1):72–81.  https://doi.org/10.1016/j.ijrobp.2015.05.004 CrossRefGoogle Scholar
  28. 28.
    Agolli L, Valeriani M, Bracci S, Nicosia L, De Sanctis V, Enrici RM, Osti MF (2015) Hypofractionated image-guided radiation therapy (3 Gy/fraction) in patients affected by inoperable advanced-stage non small cell lung cancer after long-term follow up. Anticancer Res 35(10):5693–5700Google Scholar
  29. 29.
    de Dios NR, Sanz X, Foro P, Membrive I, Reig A, Ortiz A, Jiménez R, Algara M (2017) Accelerated hypofractionated radiation therapy (AHRT) for non-small-cell lung cancer: Can we leave standard fractionation? Clin Transl Oncol 19(4):440–447.  https://doi.org/10.1007/s12094-016-1544-7 CrossRefGoogle Scholar
  30. 30.
    He J, Huang Y, Chen Y, Shi S, Ye L, Hu Y, Zhang J, Zeng Z (2016) Feasibility and efficacy of helical intensity-modulated radiotherapy for stage III non-small cell lung cancer in comparison with conventionally fractionated 3D-CRT. J Thorac Dis 8(5):862–871.  https://doi.org/10.21037/jtd.2016.03.46 CrossRefGoogle Scholar
  31. 31.
    Franceschini D, De Rose F, Cozzi L, Navarria P, Clerici E, Franzese C, Comito T, Tozzi A, Iftode C, D’Agostino G, Sorsetti M (2017) Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer: a retrospective study of elderly patients with stage III disease. Strahlenther Onkol 193(5):385–391.  https://doi.org/10.1007/s00066-017-1103-3 CrossRefGoogle Scholar
  32. 32.
    Koukourakis MI, Patlakas G, Froudarakis ME, Kyrgias G, Skarlatos J, Abatzoglou I, Bougioukas G, Bouros D (2007) Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma. Anticancer Res 27(5B):3625–3631Google Scholar
  33. 33.
    Tsoutsou PG, Froudarakis ME, Bouros D, Koukourakis MI (2008) Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC). Anticancer Res 28(2B):1349–1354Google Scholar
  34. 34.
    Matsuura K, Kimura T, Kashiwado K, Fujita K, Akagi Y, Yuki S, Murakami Y, Wadasaki K, Monzen Y, Ito A, Kagemoto M, Mori M, Ito K, Nagata Y (2009) Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer. Int J Clin Oncol 14(5):408–415.  https://doi.org/10.1007/s10147-009-0889-0 CrossRefGoogle Scholar
  35. 35.
    Casas F, Viñolas N, Ferrer F, Agustí C, Sanchez M, Maria Gimferrer J, Lomeña F, Campayo M, Jeremic B (2011) Long-term results of a phase II trial of induction paclitaxel-carboplatin followed by concurrent radiation therapy and weekly paclitaxel and consolidation paclitaxel-carboplatin in stage III non-small cell lung cancer. J Thorac Oncol 6(1):79–85.  https://doi.org/10.1097/JTO.0b013e318200e563 CrossRefGoogle Scholar
  36. 36.
    Chen C, Uyterlinde W, Sonke JJ, de Bois J, van den Heuvel M, Belderbos J (2013) Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy. Radiother Oncol 108:337–341.  https://doi.org/10.1016/j.radonc.2013.08.017 CrossRefGoogle Scholar
  37. 37.
    Lin Q, Liu YE, Ren XC, Wang N, Chen XJ, Wang DY, Zong J, Peng Y, Guo ZJ, Hu J (2013) Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial. Radiat Oncol 8(1):201.  https://doi.org/10.1186/1748-717X-8-201 CrossRefGoogle Scholar
  38. 38.
    Bearz A, Minatel E, Rumeileh IA, Borsatti E, Talamini R, Franchin G, Gobitti C, Del Conte A, Trovò M (2013) Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen. BMC Cancer 13:513.  https://doi.org/10.1186/1471-2407-13-513 CrossRefGoogle Scholar
  39. 39.
    Liu YE, Lin Q, Meng FJ, Chen XJ, Ren XC, Cao B, Wang N, Zong J, Peng Y, Ku YJ, Chen Y (2013) High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study. Radiat Oncol 8(1):198.  https://doi.org/10.1186/1748-717X-8-198 CrossRefGoogle Scholar
  40. 40.
    van den Heuvel MM, Uyterlinde W, Vincent AD, de Jong J, Aerts J, Koppe F, Knegjens J, Codrington H, Kunst PW, Dieleman E, Verheij M, Belderbos J (2014) Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating. Radiother Oncol 110(1):126–131.  https://doi.org/10.1016/j.radonc.2013.10.009 CrossRefGoogle Scholar
  41. 41.
    Ren XC, Wang QY, Zhang R, Chen XJ, Wang N, Liu YE, Zong J, Guo ZJ, Wang DY, Lin Q (2016) Accelerated hypofractionated threedimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial. BMC Cancer 16:288.  https://doi.org/10.1186/s12885-016-2314-1 CrossRefGoogle Scholar
  42. 42.
    Walraven I, van den Heuvel M, van Diessen J, Schaake E, Uyterlinde W, Aerts J, Koppe F, Codrington H, Kunst P, Dieleman E, van de Vaart P, Verheij M, Belderbos J (2016) Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. Radiother Oncol 118(3):442–446.  https://doi.org/10.1016/j.radonc.2016.02.011 CrossRefGoogle Scholar
  43. 43.
    Landau DB, Hughes L, Baker A, Bates AT, Bayne MC, Counsell N, Garcia-Alonso A, Harden SV, Hicks JD, Hughes SR, Illsley MC, Khan I, Laurence V, Malik Z, Mayles H, Mayles WPM, Miles E, Mohammed N, Ngai Y, Parsons E, Spicer J, Wells P, Wilkinson D, Fenwick JD (2016) IDEAL-CRT: a phase 1/2 trial of isotoxic dose-escalated radiation therapy and concurrent chemotherapy in patients with stage II/III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 95(5):1367–1377.  https://doi.org/10.1016/j.ijrobp.2016.03.031 CrossRefGoogle Scholar
  44. 44.
    Fowler JF (1989) Review: the linear quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62:675–679.  https://doi.org/10.1259/0007-1285-62-740-679 CrossRefGoogle Scholar
  45. 45.
    Gompelmann D, Eberhardt R, Herth FJ (2011) Advanced malignant lung disease: What the specialist can offer. Respiration 82(2):111–123.  https://doi.org/10.1159/000329703 CrossRefGoogle Scholar
  46. 46.
    Hoffmann AL, Troost EG, Huizenga H, Kaanders JH, Bussink J (2012) Individualized dose prescription for hypofractionation in advanced non-small-cell lung cancer radiotherapy: an in silico trial. Int J Radiat Oncol Biol Phys 83:1596–1602.  https://doi.org/10.1016/j.ijrobp.2011.10.032 CrossRefGoogle Scholar
  47. 47.
    Curran WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452–1460.  https://doi.org/10.1093/jnci/djr325 CrossRefGoogle Scholar
  48. 48.
    Socinski MA, Zhang C, Herndon JE, Dillman RO, Clamon G, Vokes E, Akerley W, Crawford J, Perry MC, Seagren SL, Green MR (2004) Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol 15:1033–1041.  https://doi.org/10.1093/annonc/mdh28 CrossRefGoogle Scholar

Copyright information

© Italian Society of Medical Radiology 2018

Authors and Affiliations

  • Giuseppe Parisi
    • 1
    Email author
  • Rosario Mazzola
    • 2
  • Patrizia Ciammella
    • 3
  • Giorgia Timon
    • 3
  • Alessandra Fozza
    • 4
  • Davide Franceschini
    • 5
  • Federico Navarria
    • 6
  • Alessio Bruni
    • 7
  • Marco Perna
    • 8
  • Niccolò Giaj-Levra
    • 2
  • Filippo Alongi
    • 2
  • Vieri Scotti
    • 8
  • Marco Trovo
    • 1
  1. 1.Department of Radiation OncologyAzienda Sanitaria Universitaria Integrata UDUdineItaly
  2. 2.Department of Radiation OncologySacro Cuore Don Calabria Cancer Care CenterNegrar-VeronaItaly
  3. 3.Department of Oncology and Advanced TechnologyArcispedale S Maria Nuova-IRCCS of Reggio EmiliaReggio EmiliaItaly
  4. 4.Department of Radiation OncologySS.Antonio e Biagio e C.Arrigo Hospital AlessandriaAlessandriaItaly
  5. 5.Department of Radiotherapy and RadiosurgeryHumanitas Cancer Center and Research HospitalMilanItaly
  6. 6.Department of Radiation OncologyCRO IRCCSAvianoItaly
  7. 7.Radiotherapy Unit - Department of Oncology and HematologyUniversity Hospital of Modena ItalyModenaItaly
  8. 8.Department of Radiation Oncology, Azienda Ospedaliero Universitaria CareggiUniversity of FlorenceFlorenceItaly

Personalised recommendations